SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test USA $500 | Comprehensive Cancer Risk Assessment
DNMT3A Gene AML NGS Test USA | $500 USD | Acute Myeloid Leukemia Genetic Testing | DNA Mutation Analysis DNMT3A Gene Acute Myeloid Leukemia Somatic DNMT3A Related NGS Genetic DNA Test Original price was: $700.Current price is: $500.
EGFR Gene Selective Sequencing of Exons 18-21 NGS Genetic DNA Test - $500 USA | Comprehensive Cancer Mutation Analysis EGFR Gene Selective Sequencing of Exons 18-21 NGS Genetic DNA Test Original price was: $700.Current price is: $500.
Sale!

SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test

Original price was: $700.Current price is: $500.

-29%

The SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test is a cutting-edge genetic screening that identifies mutations in the SDHD gene associated with hereditary carcinoid tumors of the intestine. Using Next-Generation Sequencing (NGS) technology, this comprehensive test provides crucial insights into inherited cancer risk, enabling early detection and personalized prevention strategies. Individuals with family history of carcinoid tumors, multiple endocrine neoplasia, or unexplained gastrointestinal symptoms should consider this test. The test costs $500 USD and offers valuable information for proactive healthcare management and family planning decisions.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test

Comprehensive Genetic Screening for Hereditary Carcinoid Cancer Risk

The SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test represents a breakthrough in personalized cancer risk assessment. This advanced genetic screening utilizes Next-Generation Sequencing (NGS) technology to detect mutations in the SDHD gene, which plays a critical role in the development of hereditary carcinoid tumors affecting the intestinal tract. Early identification of these genetic markers empowers individuals and healthcare providers to implement proactive surveillance and prevention strategies.

What This Test Measures and Detects

This sophisticated genetic analysis specifically targets the SDHD (Succinate Dehydrogenase Complex Subunit D) gene, which encodes a key component of mitochondrial complex II. The test identifies:

  • Pathogenic variants and mutations in the SDHD gene
  • Single nucleotide polymorphisms (SNPs) associated with increased cancer risk
  • Copy number variations affecting gene function
  • Inherited genetic patterns linked to familial cancer syndromes
  • Specific mutations known to predispose individuals to intestinal carcinoid tumors

Who Should Consider This Genetic Test

This comprehensive genetic screening is particularly recommended for individuals experiencing:

  • Family history of carcinoid tumors or neuroendocrine cancers
  • Personal history of multiple endocrine neoplasia type 1 or 2
  • Unexplained gastrointestinal symptoms including abdominal pain, diarrhea, or flushing
  • Family members diagnosed with SDHD-related hereditary cancer syndromes
  • Individuals with known SDHD mutations in their family lineage
  • Patients with early-onset carcinoid tumors or multiple primary tumors

Significant Benefits of Genetic Testing

Undergoing the SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test provides numerous advantages:

  • Early Risk Identification: Detect genetic predispositions before symptoms develop
  • Personalized Surveillance: Create tailored screening schedules based on individual risk
  • Family Planning Guidance: Make informed decisions about genetic inheritance
  • Proactive Prevention: Implement lifestyle and medical interventions to reduce cancer risk
  • Peace of Mind: Gain clarity about personal and familial cancer risks
  • Comprehensive Analysis: NGS technology provides thorough genetic assessment

Understanding Your Test Results

Your genetic test results will be carefully interpreted by our expert genetic counselors and oncologists:

  • Positive Result: Indicates the presence of a pathogenic SDHD mutation, requiring enhanced surveillance and potential preventive measures
  • Negative Result: No detected SDHD mutations, though continued routine screening may still be recommended
  • Variant of Uncertain Significance (VUS): Requires ongoing monitoring as research evolves
  • Family Implications: Results may impact genetic testing recommendations for blood relatives

All results include comprehensive genetic counseling to ensure complete understanding and appropriate next steps.

Test Pricing Information

Test Option Price (USD)
Discount Price $500
Regular Price $700

Nationwide Accessibility

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of certified genetic testing facilities ensures accessibility and convenience for patients nationwide.

Take Control of Your Genetic Health Today

Don’t wait to understand your genetic cancer risk profile. Our team of expert genetic counselors and oncology specialists are ready to guide you through the testing process and help interpret your results. Early detection through genetic screening can be life-saving.

Call us now at +1(267) 388-9828 to schedule your genetic counseling session and book your SDHD Gene Carcinoid Tumors Intestinal NGS Genetic DNA Test. Take the first step toward proactive cancer prevention and personalized healthcare management.

SKU: 85d6e9c8255c Category:

Related products